Reuters logo
BRIEF-Jaguar subsidiary Napo and Glenmark pharma sign agreement returning key rights in 141 countries to Napo
September 25, 2017 / 1:25 PM / 23 days ago

BRIEF-Jaguar subsidiary Napo and Glenmark pharma sign agreement returning key rights in 141 countries to Napo

Sept 25 (Reuters) - Glenmark Pharmaceuticals Ltd

* Jaguar subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals sign agreement returning key rights in 141 countries to Napo, solidifying Jaguar’s global commercial control of Mytesi (Crofelemer), Jaguar’s fda-approved human drug

* Jaguar Health- Glenmark will continue to serve as CGMP-compliant commercial manufacturer of Crofelemer for Jaguar and Napo at its FDA-approved facilities in India

* Jaguar Health- agreement also provides Napo with commercial rights to existing regulatory approvals for Crofelemer in Brazil, Ecuador, Zimbabwe & Botswana Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below